Related Experiment Video
Updated: Jun 1, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
New short interfering RNA-based therapies for glomerulonephritis
Hideki Shimizu1, Toshiro Fujita
1Department of Nephrology and Endocrinology, University of Tokyo School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Nature Reviews. Nephrology
|May 26, 2011
Summary
Short interfering RNAs (siRNAs) offer promising gene-silencing therapy for glomerulonephritis. However, challenges in targeted delivery to the glomerulus must be addressed for successful clinical application.
Area of Science:
- Nephrology
- Molecular Biology
- Biotechnology
Background:
- Current glomerulonephritis treatments are inadequate, necessitating novel therapeutic strategies.
- Short interfering RNAs (siRNAs) show potential for targeted gene silencing in molecular therapy.
- Existing siRNA research faces challenges in clinical translation, particularly for systemic diseases.
Purpose of the Study:
- To review the challenges in developing siRNA-based therapies for glomerulonephritis.
- To highlight the specific difficulties in achieving glomerulus-specific siRNA delivery.
- To explore novel delivery strategies for glomerulus-targeted siRNA therapies.
Main Methods:
- Literature review of current siRNA therapy research.
- Analysis of challenges in in vivo siRNA delivery for kidney diseases.
- Discussion of emerging delivery systems for glomerular targeting.
Main Results:
- siRNA therapy holds promise for glomerulonephritis but lacks established tissue-specific delivery protocols.
- Targeting the glomerulus specifically remains a significant hurdle for systemic siRNA application.
- Novel delivery approaches are being developed to overcome current limitations.
Conclusions:
- Effective siRNA-based therapies for glomerulonephritis require overcoming significant delivery challenges.
- Glomerulus-specific targeting is critical for advancing siRNA treatments for this condition.
- Further research into novel delivery systems is essential for clinical translation.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...